These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 793488)

  • 1. Discussion paper: effect on IgG1 class alloantibody on retention of skin allografts and on tumor growth in the mouse.
    Harris TN; Harris S
    Ann N Y Acad Sci; 1976; 277(00):700-5. PubMed ID: 793488
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhancement of growth of allogeneic mouse tumor by the IgG1 fraction of alloantibody preparations.
    Harris TN; Harris S; Henri EM; Farber MB
    J Natl Cancer Inst; 1978 Jan; 60(1):167-72. PubMed ID: 628014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloantibodies in relation to the rejection of skin allografts in the mouse.
    Harris TN; Harris S
    Adv Exp Med Biol; 1976; 73 Pt B():253-67. PubMed ID: 793335
    [No Abstract]   [Full Text] [Related]  

  • 4. Various effects of alloantibody-containing globulins on the time of retention of skin allografts in the mouse.
    Harris TN; Harris S; Bocchieri MH; Farber MB; Ogburn CA
    Transplantation; 1972 Oct; 14(4):495-500. PubMed ID: 4566165
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunogenicity and enhancement of normal and tumor tissue in the mouse.
    McKenzie IF; Snell GD
    Transplant Proc; 1973 Mar; 5(1):953-6. PubMed ID: 4572155
    [No Abstract]   [Full Text] [Related]  

  • 6. Shifts from IgG-2 class to IgG-1 class in CBA and C3H anti-BALB/c antibody.
    Harris TN; Harris S
    Transplantation; 1975 Apr; 19(4):318-25. PubMed ID: 1098236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antigen driven selection for Fc receptors of enhancing antibody on macrophages during an alloimmune response.
    Whitten HD; Cruse JM; Lewis GK; Watson ES
    J Reticuloendothel Soc; 1974 Feb; 15(2):118-25. PubMed ID: 4815211
    [No Abstract]   [Full Text] [Related]  

  • 8. Facilitation of macrophage-mediated destruction of allogeneic fibrosarcoma cells by tumor-enhancing IgG 2 in vitro.
    Cruse JM; Whitten HD; Lewis GK; Watson ES
    Transplant Proc; 1973 Mar; 5(1):961-7. PubMed ID: 4695960
    [No Abstract]   [Full Text] [Related]  

  • 9. Tumor cell-related syngeneic skin graft rejection in gross leukemia.
    Mariani T; Maruyama Y; Good RA
    Natl Cancer Inst Monogr; 1972 Dec; 35():309-20. PubMed ID: 4572830
    [No Abstract]   [Full Text] [Related]  

  • 10. Skin grafts in nude mice. 1. Allografts in nude mice of three genetic backgrounds (BALB-c, C3H, C57-BL).
    Rygaard J
    Acta Pathol Microbiol Scand A; 1974 Jan; 82(1):80-92. PubMed ID: 4597211
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of anti-H-2K and H-2D alloantibodies in enhancement and acute antibody-mediated rejection of mouse skin allografts.
    de Waal RM; Capel PJ; Koene RA
    J Immunol; 1980 Feb; 124(2):719-23. PubMed ID: 6985936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of GK1.5 and chimeric rat/mouse GK1.5 anti-CD4 antibodies for prolongation of skin allograft survival and suppression of alloantibody production in mice.
    Rashid A; Auchincloss H; Sharon J
    J Immunol; 1992 Mar; 148(5):1382-8. PubMed ID: 1538121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperacute rejection of skin allografts in the mouse by the administration of alloantibody and rabbit complement.
    Koene RA; Gerlag PG; Hagemann JF; van Haelst UJ; Wijdeveld PG
    J Immunol; 1973 Aug; 111(2):520-6. PubMed ID: 4577882
    [No Abstract]   [Full Text] [Related]  

  • 14. Enhancing alloantibody effective during sensitization but not effector phase of skin graft rejection.
    Sugarbaker PH; Chang AE
    Transplantation; 1979 Jul; 28(1):60-5. PubMed ID: 377597
    [No Abstract]   [Full Text] [Related]  

  • 15. Prolonged survival of murine fibrosarcoma allotransplants by anti-enhancing Fab alloantibody.
    Cruse JM; Lewis GK; Whitten HD; Watson ES; Hester RB; Fields JF
    Immunol Commun; 1972; 1(4):367-73. PubMed ID: 4548901
    [No Abstract]   [Full Text] [Related]  

  • 16. Fate of skin allografts in normal mice injected with antigraft strain globulin in relation to the IgG1 and IgG2 class of the antibodies.
    Harris TN; Harris S
    Immunology; 1973 Sep; 25(3):409-21. PubMed ID: 4582458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of antigraft strain antibodies on skin allografts in immunologically tolerant mice.
    Harris TN; Harris S; Farber MB
    Transplantation; 1973 Apr; 15(4):383-8. PubMed ID: 4145731
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of IgG and IgM alloantibodies in the enhancement of mouse skin allografts and the relation with their opsonizing capacity in vivo.
    Lems SP; Tamboer WP; Capel PJ; Koene RA
    J Immunol; 1981 Aug; 127(2):665-9. PubMed ID: 7019328
    [No Abstract]   [Full Text] [Related]  

  • 19. Orthotopic bone transplantation in mice. II. Studies of the alloantibody response.
    Halloran PF; Lee EH; Ziv I; Langer F; Gross AE
    Transplantation; 1979 Jun; 27(6):420-6. PubMed ID: 380081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dynamics of immunity in syngeneic lymphoma-bearing mice.
    Jurin M; Plavsić B
    Eur J Cancer (1965); 1978 Jun; 14(6):653-9. PubMed ID: 350589
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.